When was Phastar founded?

Phastar was founded in 2007 and raised its 1st funding round 14 years after it was founded.

Where is Phastar located?

Phastar is headquartered in London, United Kingdom.

Who is the current CEO of Phastar?

Kevin Kane of Phastar. They have also founded 1 company.

How many employees does Phastar have?

As of Sep 30, 2026, the latest employee count at Phastar is 376.

Is Phastar a funded company?

Phastar is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on Jan 05, 2021.

When was the latest funding round of Phastar?

Phastar's latest funding was a $***** PE round on Jan 05, 2021, with participation from 1 investor.

Where does Phastar rank among its competitors?

Phastar ranks 7th amongst 178 active competitors, of which 9 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Clinilabs, which secured an undisclosed amount in Mar, 2025.

Who are the top competitors of Phastar?

Phastar's top competitors include SSI Strategy, Fusion Antibodies and IDDI. Among them, Clinilabs secured the most recent funding round in March, 2025.

Phastar - 2026 Company Profile, Team, Funding & Competitors

Company Details

Phastar is a specialist CRO offering statistical services to support clinical trials. The company's services include statistical input into study design and protocol development, adaptive study designs, sample size calculations, analysis plans, optimising study success, identifying the primary endpoint, modelling and simulation, prediction of drug exposure, optimal evaluation of information for on-going clinical trials, regulatory advice, observational and epidemiological studies, interpretation of results, data visualisation, statistical training, etc.

Website: phastar.com
Social

Key Metrics

Founded Year

2007

Location

London, United Kingdom

Stage

Late Stage

Latest Funding Round

PE, Jan 05, 2021, $*****

Investors

Charterhouse Capital Partners

Ranked

7^th among 178 active competitors

Employee Count

376 as on Sep 30, 2026

Similar Companies

SSI Strategy & 223 more

View Phastar's full profile

Phastar has raised funding over 1 round. Its latest funding round was a PE round on Jan 05, 2021 for $*****. 1 investor participated in its latest round. Phastar has 1 institutional investor.

Here is the list of recent funding rounds of Phastar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 05, 2021	1132601	PE	2851404	2997299	1562768	4769348

Access funding benchmarks and valuations. Sign up today!

View details of Phastar's funding rounds and investors

The founders of Phastar is Kevin Kane. Kevin Kane is the CEO of Phastar.

Here are the details of Phastar's key team members:

Kevin Kane: Founder & CEO of Phastar.

View details of Phastar's Founder profiles and Board Members

Phastar's employee count trend

Phastar has 376 employees as of Sep 26. Here is Phastar's employee count trend over the years:

Uncover Phastar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Phastar include SSI Strategy, Fusion Antibodies and IDDI. Here is the list of Top 10 competitors of Phastar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	SSI Strategy 2010, Parsippany Troy Hills (United States), Acquired	Strategic partner for biotech companies, from concept to commercialization	-	Amulet Capital Partners, Sterling Investment Partners ... & 3 others	64/100
2nd	Fusion Antibodies 2001, Belfast (United Kingdom), Public	Company offering a range of services in antibody production, development, characterization and optimization right from discovery to commercialization	$2.5M	Viridian Investment Partners, Qubis & 4 others	56/100
3rd	IDDI 1991, Louvain la Neuve (Belgium), Series A	Provider of bio-statistics and e-clinical services	-	SRIW	51/100
4th	ProductLife Group 2000, Suresnes (France), Acquired	Regulatory support and pharmacovigilance services for drug development	-	-	50/100
5th	Health Decisions 1989, Durham (United States), Acquired	CRO focused on clinical trial services for data management, monitoring and biostatistics	$1.8M	Excelerate Health Ventures, Boston Millennia Partners ... Read more	46/100
6th	August Research 2012, Sofia (Bulgaria), Acquired	Clinical trial services in Central and Eastern Europe.	-	-	45/100
7th	Phastar 2007, London (United Kingdom), Late Stage	Statistical consulting, clinical trial reporting and data management services.	-	Charterhouse Capital Partners	34/100
8th	ABEC 1974, Bethlehem (United States), Unfunded	Manufacturer of stainless steel and single-use bioprocess solutions. This provider designs, engineers, and manufactures bioprocess equipment and systems for biopharmaceutical production. Services include process engineering, equipment installation and qualification, and ongoing maintenance and support. A focus on customized solutions allows clients to accelerate the design and build of complete bioprocess lines, and deliver customized single-use disposable containers. The company offers support across the entire bioprocess, setting new benchmarks in time to market.	-	-	39/100
9th	Alcedis 1992, Giessen (Germany), Acquired	Alcedis offers IT solutions and services for clinical research.	-	-	39/100
10th	Clinilabs 2001, New York City (United States), Late Stage	A full-service contract research organisation	-	InTandem Capital Partners	38/100